MRK - Merck & Co., Inc.
81.60 +0.01 (0.01%)
After hours: 6:00PM EDT
| Previous close | 80.96 |
| Open | 81.32 |
| Bid | 81.30 x 2200 |
| Ask | 81.60 x 900 |
| Day's range | 80.89 - 81.78 |
| 52-week range | 62.01 - 87.07 |
| Volume | 6,772,502 |
| Avg. volume | 11,308,327 |
| Market cap | 210.065B |
| Beta (3Y monthly) | 0.33 |
| PE ratio (TTM) | 25.76 |
| EPS (TTM) | 3.17 |
| Earnings date | 30 Jul 2019 |
| Forward dividend & yield | 2.20 (2.72%) |
| Ex-dividend date | 2019-06-14 |
| 1y target est | 92.14 |
- Zacks•1 hour ago
Merck (MRK) Gains As Market Dips: What You Should Know
Merck (MRK) closed the most recent trading day at $81.59, moving +0.78% from the previous trading session.
- Zacks•3 hours ago
Is a Beat in the Cards for Novartis' (NVS) Q2 Earnings?
Investors will focus on regular top- and bottom-line numbers along with pipeline updates when Novartis (NVS) reports second-quarter results.
- Zacks•8 hours ago
Glaxo's Zejula Meets Goal in First-Line Ovarian Cancer Study
Glaxo's (GSK) phase III study evaluating Zejula as a first-line maintenance therapy in patients with ovarian cancer meets the primary endpoint.
- Zacks•9 hours ago
The Zacks Analyst Blog Highlights: Cisco, Home Depot, Merck, Humana and Public Service Enterprise
The Zacks Analyst Blog Highlights: Cisco, Home Depot, Merck, Humana and Public Service Enterprise
- Zacks•9 hours ago
J&J (JNJ) Beats on Q2 Earnings, Ups 2019 Sales Growth View
J&J (JNJ) beats estimates for both earnings and sales in the second quarter of 2019 and raises 2019 guidance for operational sales growth for the second time this year.
- Zacks•yesterday
Top Stock Reports for Cisco, Home Depot & Merck
Top Stock Reports for Cisco, Home Depot & Merck
- Zacks•yesterday
J&J Falls Amid Reports of Criminal Probe Into Talcum Powder
The U.S. Justice Department is reportedly pursuing a criminal investigation as to whether J&J (JNJ) lied about the possible cancer risk associated with its talcum powder.
- Reuters - UK Focus•yesterday
UPDATE 2-GSK drug helps ovarian cancer patients live longer in late-stage study
GlaxoSmithKline Plc's cancer treatment Zejula met the main goal of helping patients with ovarian cancer live longer without their disease worsening in a late-stage study, the company said on Monday. The company bought the drug when it acquired U.S. cancer specialist Tesaro for $5.1 billion in December and Zejula is already approved for certain ovarian cancer patients. For GSK, the success of Zejula would help it access a wider population group and give it an edge over rival PARP inhibitors such as AstraZeneca and Merck & Co's Lynparza and Clovis Oncology's Rubraca.
- Motley Fool•3 days ago
Better Buy: AbbVie vs. Merck
Which stock wins in a head-to-head matchup between these two big drugmakers?
- CNBC•4 days ago
Stocks making the biggest moves midday: Johnson & Johnson, Stitch Fix, Illumina, Merck & more
These are the stocks posting the largest moves in midday trading.
- Zacks•4 days ago
Drug Pricing Woes Linger on Repealing Drug Rebate Proposal
Investors' skepticism runs rife as Trump drops the drug rebate proposal, pushing drugmakers to take center stage with regard to the controversial drug pricing issue.
- Zacks•4 days ago
AstraZeneca's Imfinzi Gains Orphan Drug Status for SCLC
The FDA assigns an orphan drug designation to AstraZeneca's (AZN) Imfinzi for the treatment of small cell lung cancer, the most aggressive type of the ailment.
- Zacks•4 days ago
Dow Breezes Past 27,000: 4 Blue-Chip Stocks to Buy
The 30-stock index closes above the 27,000 mark for the first time. It took nearly 372 days for the blue-chip index to cross the 27,000 mark from when it reached the 26,000 mark in January 2018.
- Zacks•4 days ago
Dow 30 Stock Roundup: Cisco to Buy Acacia, Microsoft & ServiceNow Partnernership
The index endured a turbulent week but gained after the Fed Chair indicated that a rate was likely later this month.
- Zacks•4 days ago
Pharma Stock Roundup: Pipeline & Regulatory Updates by MRK, GSK, SNY
Glaxo (GSK) provides updates on HIV regimens. FDA accepts Merck (MRK) & Sanofi's (SNY) regulatory applications for review.
- Zacks•5 days ago
Trump Drops Drug Rebate Proposal: What's Next and What Stocks to Play
The Trump administration announced Thursday that it's deciding to withdraw its proposal to eliminate rebates from government drug plans.
- Reuters - UK Focus•5 days ago
US STOCKS-S&P 500, Dow climb as health insurers, financials gain
The Dow and S&P 500 rose on Thursday to close at record highs as health insurers gained after the Trump administration scrapped a plan designed to rein in prescription drug prices, while financial shares climbed with bond yields. A 5.5% gain in UnitedHealth Group Inc helped the Dow close above 27,000 points for the first time.
- Yahoo Finance•5 days ago
Drug distributors surge, drug makers tumble after Trump administration reverses stance on rebates
The drug companies provide rebates to PBMs in exchange for distributing their products.
- Zacks•5 days ago
Bristol-Myers (BMY) Down 11.6% YTD: What Lies Ahead in 2H19?
Bristol-Myers (BMY) declines on uncertainty and delay of the Celgene merger.
- Reuters - UK Focus•5 days ago
CORRECTED-US STOCKS-S&P 500 near flat as healthcare in spotlight
The S&P 500 was little changed in afternoon trading on Thursday, with healthcare stocks mixed after the Trump administration withdrew a rule that would kill rebates. Shares of pharmacy benefit managers gained as the news meant these companies would continue to benefit from after-market discounts from drugmakers. A 5.3% gain in UnitedHealth Group Inc helped the Dow break above 27,000 points for the first time.
- Investing.com•5 days ago
Stocks - Dow Tops 27,000 as UnitedHealth Soars
Investing.com – The Dow hit a new high as it topped 27,000 for the first time on Thursday thanks to a huge gain for health insurance giant UnitedHealth Group and sizable for gains for Boeing (NYSE:BA) and Goldman Sachs (NYSE:GS).
- Zacks•5 days ago
4 Medical Stocks to Consider After Federal Judge Blocks Trump Proposal
In early May, President Donald Trump announced that he would be requiring Big Pharma to list the prices of their drugs in their TV advertisements.
- Zacks•5 days ago
FDA Accepts Sanofi's BLA for Myeloma Candidate to Review
The FDA accepts for review Sanofi's (SNY) BLA for isatuximab as a potential treatment for relapsed/refractory multiple myeloma. The FDA will declare its decision by April 2020.
- Zacks•5 days ago
J&J (JNJ) to Kick-Start Pharma Q2 Earnings: A Beat in Store?
J&J's (JNJ) cancer drugs should continue to perform well in second-quarter 2019. Generic/biosimilar headwinds will hurt Pharma unit's sales.
- Investing.com•5 days ago
Stocks - Health Insurers Drive Dow to New Record at Opening
Investing.com -- Wall Street rose at the open on Thursday, as healthcare stocks reacted exuberantly to the administration abandoning a plan to curb drug rebates from government drug plans, pushing the Dow Jones Industrial Average above 27,000 for the first time.
